Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Correction: Genetically enhanced T lymphocytes and the intensive care unit.

Tat T, Li H, Constantinescu CS, Onaciu A, Chira S, Osan C, Pasca S, Petrushev B, Moisoiu V, Micu WT, Berce C, Tranca S, Dima D, Berindan-Neagoe I, Shen J, Tomuleasa C, Qian L.

Oncotarget. 2018 Aug 10;9(62):32097. doi: 10.18632/oncotarget.25983. eCollection 2018 Aug 10.

2.

Premature senescence activation in DLD-1 colorectal cancer cells through adjuvant therapy to induce a miRNA profile modulating cellular death.

Chira S, Raduly L, Braicu C, Jurj A, Cojocneanu-Petric R, Pop L, Pileczki V, Ionescu C, Berindan-Neagoe I.

Exp Ther Med. 2018 Aug;16(2):1241-1249. doi: 10.3892/etm.2018.6324. Epub 2018 Jun 19.

3.

Genetically enhanced T lymphocytes and the intensive care unit.

Tat T, Li H, Constantinescu CS, Onaciu A, Chira S, Osan C, Pasca S, Petrushev B, Moisoiu V, Micu WT, Berce C, Tranca S, Dima D, Berindan-Neagoe I, Shen J, Tomuleasa C, Qian L.

Oncotarget. 2018 Mar 27;9(23):16557-16572. doi: 10.18632/oncotarget.24637. eCollection 2018 Mar 27. Review. Erratum in: Oncotarget. 2018 Aug 10;9(62):32097.

4.

Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.

Tomuleasa C, Fuji S, Berce C, Onaciu A, Chira S, Petrushev B, Micu WT, Moisoiu V, Osan C, Constantinescu C, Pasca S, Jurj A, Pop L, Berindan-Neagoe I, Dima D, Kitano S.

Front Immunol. 2018 Feb 19;9:239. doi: 10.3389/fimmu.2018.00239. eCollection 2018. Review.

5.

Restoring the p53 'Guardian' Phenotype in p53-Deficient Tumor Cells with CRISPR/Cas9.

Chira S, Gulei D, Hajitou A, Berindan-Neagoe I.

Trends Biotechnol. 2018 Jul;36(7):653-660. doi: 10.1016/j.tibtech.2018.01.014. Epub 2018 Feb 22. Review.

6.

CRISPR/Cas9: Transcending the Reality of Genome Editing.

Chira S, Gulei D, Hajitou A, Zimta AA, Cordelier P, Berindan-Neagoe I.

Mol Ther Nucleic Acids. 2017 Jun 16;7:211-222. doi: 10.1016/j.omtn.2017.04.001. Epub 2017 Apr 8. Review.

7.

Dietary Intervention by Phytochemicals and Their Role in Modulating Coding and Non-Coding Genes in Cancer.

Budisan L, Gulei D, Zanoaga OM, Irimie AI, Sergiu C, Braicu C, Gherman CD, Berindan-Neagoe I.

Int J Mol Sci. 2017 Jun 1;18(6). pii: E1178. doi: 10.3390/ijms18061178. Review.

8.

Novel insight into triple-negative breast cancers, the emerging role of angiogenesis, and antiangiogenic therapy.

Braicu C, Chiorean R, Irimie A, Chira S, Tomuleasa C, Neagoe E, Paradiso A, Achimas-Cadariu P, Lazar V, Berindan-Neagoe I.

Expert Rev Mol Med. 2016 Nov 7;18:e18. Review.

PMID:
27817751
9.

Effects of Cd2+ on the epithelial Na+ channel (ENaC) investigated by experimental and modeling studies.

Mernea M, Ulăreanu R, Călborean O, Chira S, Popescu O, Mihailescu DF, Cucu D.

Gen Physiol Biophys. 2016 Jul;35(3):259-71. doi: 10.4149/gpb_2015054. Epub 2016 Apr 5.

PMID:
27045669
10.

Progresses towards safe and efficient gene therapy vectors.

Chira S, Jackson CS, Oprea I, Ozturk F, Pepper MS, Diaconu I, Braicu C, Raduly LZ, Calin GA, Berindan-Neagoe I.

Oncotarget. 2015 Oct 13;6(31):30675-703. doi: 10.18632/oncotarget.5169. Review.

11.

Pharmacokinetics Evaluation of Carbon Nanotubes Using FTIR Analysis and Histological Analysis.

Gherman C, Tudor MC, Constantin B, Flaviu T, Stefan R, Maria B, Chira S, Braicu C, Pop L, Petric RC, Berindan-Neagoe I.

J Nanosci Nanotechnol. 2015 Apr;15(4):2865-9.

PMID:
26353506
12.

Dual targeted therapy with p53 siRNA and Epigallocatechingallate in a triple negative breast cancer cell model.

Braicu C, Pileczki V, Pop L, Petric RC, Chira S, Pointiere E, Achimas-Cadariu P, Berindan-Neagoe I.

PLoS One. 2015 Apr 7;10(4):e0120936. doi: 10.1371/journal.pone.0120936. eCollection 2015.

13.

Clinical and pathological implications of miRNA in bladder cancer.

Braicu C, Cojocneanu-Petric R, Chira S, Truta A, Floares A, Petrut B, Achimas-Cadariu P, Berindan-Neagoe I.

Int J Nanomedicine. 2015 Jan 20;10:791-800. doi: 10.2147/IJN.S72904. eCollection 2015. Review.

14.

TIMP-1 expression in human colorectal cancer is associated with SMAD3 gene expression levels: a pilot study.

Ionescu C, Braicu C, Chiorean R, Cojocneanu Petric R, Neagoe E, Pop L, Chira S, Berindan-Neagoe I.

J Gastrointestin Liver Dis. 2014 Dec;23(4):413-8. doi: 10.15403/jgld.2014.1121.234.smad.

15.

The non-autonomous retrotransposon SVA is trans-mobilized by the human LINE-1 protein machinery.

Raiz J, Damert A, Chira S, Held U, Klawitter S, Hamdorf M, Löwer J, Strätling WH, Löwer R, Schumann GG.

Nucleic Acids Res. 2012 Feb;40(4):1666-83. doi: 10.1093/nar/gkr863. Epub 2011 Nov 3.

Supplemental Content

Loading ...
Support Center